Currently, many AmeriHealth members who receive infliximab (Remicade^®) do so in their physician's office, which AmeriHealth recognizes as a cost-effective setting. However, some physicians send their patients to an outpatient facility, where treatment costs may be higher.

For physicians who do not administer in-office infusions, there are two treatment options that may be more cost-effective than the outpatient facility: freestanding infusion suites and home infusion providers. Freestanding in-network infusion suites are becoming popular treatment sites for members to receive infusion drugs like Remicade^®. As a result, Walgreens is reaching out to select network physicians whose AmeriHealth patients typically receive Remicade^® in an outpatient facility setting. Walgreens will discuss the Walgreens Site of Care Optimization Program and highlight the benefits of administering Remicade^® in Walgreens infusion suites.

Members who currently receive Remicade^® in an outpatient facility setting may also be able to have it administered in their home through an AmeriHealth-approved home infusion provider. Many members choose home infusion therapy because they can coordinate their treatment based on their schedule and receive treatment in the comfort and convenience of their own home.

Over the next few months, AmeriHealth will send letters to our members to educate them about these additional treatment options and the advantages in terms of safety, convenience, and potentially lower out-of-pocket costs.

To learn more about options for the administration of Remicade^® in an infusion suite or the member's home, call Customer Service
at 1-800-275-2583 for providers in Pennsylvania and Delaware or at 1-888-YOUR-AH1 (1-888-968-7241) for providers in New Jersey.